- Home
- QURE
QURE
uniQure N.V.
as 07-26-2024 4:00pm EST
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Upcoming Earnings Alert:
Get ready for potential market movements as uniQure N.V. QURE prepares to release earnings report on 30 Jul 2024.
| Founded: | 1998 | Country: | Netherlands |
| Employees: | N/A | City: | AMSTERDAM |
| Market Cap: | 432.6M | IPO Year: | 2007 |
| Target Price: | $23.50 | AVG Volume (30 days): | 7.7M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.73 - $11.35 | Next Earning Date: | 07-30-2024 |
| Revenue: | $19,003,000 | Revenue Growth: | -82.73% |
| Revenue Growth (this year): | 265.61% | Revenue Growth (next year): | 74.54% |
Stock Insider Trading Activity of uniQure N.V. (QURE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | QURE | Chief Medical Officer | Jun 26 '24 | Sell | $4.36 | 1,447 | $6,308.92 | 115,253 | SEC Form 4 |
| KLEMT CHRISTIAN | QURE | Chief Financial Officer | Jun 17 '24 | Sell | $4.80 | 1,611 | $7,732.80 | 164,837 | SEC Form 4 |
| CALOZ PIERRE | QURE | Chief Operating Officer | Jun 17 '24 | Sell | $4.81 | 2,936 | $14,122.16 | 115,707 | SEC Form 4 |
| Gut Robert | QURE | Director | Jun 13 '24 | Sell | $5.12 | 3,504 | $17,940.48 | 44,165 | SEC Form 4 |
| Balachandran Madhavan | QURE | Director | Jun 13 '24 | Sell | $5.12 | 2,231 | $11,422.72 | 23,759 | SEC Form 4 |
| Jacques Rachelle Suzanne | QURE | Director | Jun 13 '24 | Sell | $5.14 | 2,221 | $11,415.94 | 14,408 | SEC Form 4 |
| Soteropoulos Paula | QURE | Director | Jun 13 '24 | Sell | $5.14 | 2,220 | $11,410.80 | 20,203 | SEC Form 4 |
| POST LEONARD E | QURE | Director | Jun 13 '24 | Sell | $5.14 | 2,222 | $11,421.08 | 15,999 | SEC Form 4 |
| Potts Jeannette | QURE | Chief Legal Officer | Jun 13 '24 | Sell | $4.98 | 4,781 | $23,809.38 | 91,819 | SEC Form 4 |
| Meek David D. | QURE | Director | Jun 13 '24 | Sell | $5.12 | 2,229 | $11,412.48 | 20,252 | SEC Form 4 |
| Kaye Jack | QURE | Director | Jun 13 '24 | Sell | $5.16 | 2,218 | $11,444.88 | 6,501 | SEC Form 4 |
| CALOZ PIERRE | QURE | Chief Operating Officer | Feb 26 '24 | Sell | $6.47 | 9,455 | $61,173.85 | 85,643 | SEC Form 4 |
| Kapusta Matthew C | QURE | CEO, Managing Director | Feb 26 '24 | Sell | $6.35 | 27,904 | $177,190.40 | 440,839 | SEC Form 4 |
| KLEMT CHRISTIAN | QURE | Chief Financial Officer | Feb 26 '24 | Sell | $6.38 | 15,906 | $101,480.28 | 116,948 | SEC Form 4 |
Latest uniQure N.V. News
QURE Breaking Stock News: Dive into QURE Ticker-Specific Updates for Smart Investing
Zacks
11 hours ago
Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?
MT Newswires
3 days ago
UniQure Completes Sale of Facility to Genezen
GlobeNewswire
4 days ago
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
Clinical Trials Arena
15 days ago
uniQure’s shares soar on positive data for Huntington’s gene therapy
Zacks
15 days ago
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
Zacks
16 days ago
Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
Zacks
16 days ago
uniQure (QURE) Soars on New Huntington's Disease Study Data
Zacks
17 days ago
uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?
Compare QURE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QURE uniQure N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.